PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35580917-9 2022 In addition, treatment with vinpocetine suppressed protein expression of Nrf2 and inhibited messenger RNA levels of heme oxygenase 1 and NAD(P)H dehydrogenase quinone 1 induced by cisplatin. Cisplatin 180-189 heme oxygenase 1 Homo sapiens 116-132 31983246-0 2020 Thymoquinone and Curcumin combination protects cisplatin-induced Kidney Injury, Nephrotoxicity by attenuating NFkB, KIM-1 and ameliorating Nrf2/HO-1 signaling. Cisplatin 47-56 heme oxygenase 1 Homo sapiens 144-148 35490795-0 2022 Induction of ferroptosis by carnosic acid-mediated inactivation of Nrf2/HO-1 potentiates cisplatin responsiveness in OSCC cells. Cisplatin 89-98 heme oxygenase 1 Homo sapiens 72-76 35490795-9 2022 Furthermore, compared with parental cells, stronger activation of the Nrf2/HO-1/xCT signaling was observed in cisplatin-resistant cells, which was inhibited by carnosic acid. Cisplatin 110-119 heme oxygenase 1 Homo sapiens 75-79 35490795-11 2022 Together, the current findings highlight that carnosic acid may re-sensitize cisplatin-resistant cells to cisplatin by inducing ferroptosis, which involves the inactivation of Nrf2/HO-1/xCT pathway. Cisplatin 77-86 heme oxygenase 1 Homo sapiens 181-185 35490795-11 2022 Together, the current findings highlight that carnosic acid may re-sensitize cisplatin-resistant cells to cisplatin by inducing ferroptosis, which involves the inactivation of Nrf2/HO-1/xCT pathway. Cisplatin 106-115 heme oxygenase 1 Homo sapiens 181-185 33232319-0 2020 LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1. Cisplatin 28-37 heme oxygenase 1 Homo sapiens 88-92 33232319-9 2020 Furthermore, Nrf2 and HO-1 mRNA levels, as critical molecules in the oxidative stress pathway, were inhibited by siRNAs targeting MIR4435-2HG, suggesting that MIR4435-2HG-mediated cisplatin resistance occurs through the Nrf2/HO-1 pathway. Cisplatin 180-189 heme oxygenase 1 Homo sapiens 22-26 33232319-9 2020 Furthermore, Nrf2 and HO-1 mRNA levels, as critical molecules in the oxidative stress pathway, were inhibited by siRNAs targeting MIR4435-2HG, suggesting that MIR4435-2HG-mediated cisplatin resistance occurs through the Nrf2/HO-1 pathway. Cisplatin 180-189 heme oxygenase 1 Homo sapiens 225-229 31983246-11 2020 In summary, Tq + Cur had protective effects on cisplatin-induced nephrotoxicity and renal injury, which could be mediated by up-regulation of survival signals like Akt, Nrf2/HO-1, and attenuation of KIM-1, NFkB. Cisplatin 47-56 heme oxygenase 1 Homo sapiens 174-178 32240302-0 2020 JUND-dependent upregulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer. Cisplatin 56-65 heme oxygenase 1 Homo sapiens 31-36 32574971-7 2020 The underlying mechanisms of monotropein on alleviating cisplatin-induced AKI were associated with the activation of Nrf2/HO-1 pathway against oxidative stress and the inhibition on NF-kappaB signaling to suppress inflammation as well as the regulation on the expressions of proteins in apoptosis pathway in this renal injury model. Cisplatin 56-65 heme oxygenase 1 Homo sapiens 122-126 32817372-7 2020 In parallel with decreased GULP1 expression, we observed increased expression of NRF2, HMOX1, and other candidate antioxidant genes in cisplatin-resistant cells. Cisplatin 135-144 heme oxygenase 1 Homo sapiens 87-92 32209424-0 2020 New insights into the protection of growth hormone in cisplatin-induced nephrotoxicity: The impact of IGF-1 on the Keap1-Nrf2/HO-1 signaling. Cisplatin 54-63 heme oxygenase 1 Homo sapiens 126-130 32209424-7 2020 Cisplatin upregulated the HMGB-1/NF-kappaB and downregulated Nrf2/HO-1 pathways which were reversed by hGH and aligned with increased renal IGF-1 expression. Cisplatin 0-9 heme oxygenase 1 Homo sapiens 66-70 32209424-10 2020 SIGNIFICANCE: these results concluded that hGH can attenuate the inflammation and oxidative stress attained by CDDP probably through inhibition of Nrf2/HO-1 pathway. Cisplatin 111-115 heme oxygenase 1 Homo sapiens 152-156 32209424-11 2020 We also suggested that Keap1/Nrf2-mediated upregulation of the antioxidant HO-1 might inhibit HMGB-1/NF-kappaB signaling and thus provide the principal protection mechanism offered by hGH against CDDP-induced kidney injury. Cisplatin 196-200 heme oxygenase 1 Homo sapiens 75-79 31659617-0 2019 Grape Seed Procyanidins Attenuates Cisplatin-induced Human Embryonic Renal Cell Cytotoxicity by Modulating Heme Oxygenase-1 in Vitro. Cisplatin 35-44 heme oxygenase 1 Homo sapiens 107-123 31659617-3 2019 This study reported whether O-GSP can antagonize the cisplatin-induced cytotoxicity in HEK293 cells through inducing HO-1 protein expression. Cisplatin 53-62 heme oxygenase 1 Homo sapiens 117-121 31659617-5 2019 Herein, We found that O-GSP can antagonize cisplatin nephrotoxicity through regulating the expression of HO-1. Cisplatin 43-52 heme oxygenase 1 Homo sapiens 105-109 31877176-0 2019 alpha-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway. Cisplatin 35-44 heme oxygenase 1 Homo sapiens 85-89 31559456-0 2019 Epidermal growth factor receptor/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens. Cisplatin 89-98 heme oxygenase 1 Homo sapiens 33-49 31659617-8 2019 And O-GSP can modulate the decrease of Nrf2 and HO-1 expression induced by cisplatin, and improve the cisplatin-induced activity and apoptosis rate of cells by stimulating the expression of HO-1. Cisplatin 75-84 heme oxygenase 1 Homo sapiens 48-52 31659617-8 2019 And O-GSP can modulate the decrease of Nrf2 and HO-1 expression induced by cisplatin, and improve the cisplatin-induced activity and apoptosis rate of cells by stimulating the expression of HO-1. Cisplatin 102-111 heme oxygenase 1 Homo sapiens 190-194 31559456-1 2019 PURPOSE: To investigate the possibility that the antioxidant stress protein Heme oxygenase-1 (HO-1) is involved in the acquisition of chemoresistance in cisplatin and pirarubicin (CITA) therapy. Cisplatin 153-162 heme oxygenase 1 Homo sapiens 76-92 31559456-1 2019 PURPOSE: To investigate the possibility that the antioxidant stress protein Heme oxygenase-1 (HO-1) is involved in the acquisition of chemoresistance in cisplatin and pirarubicin (CITA) therapy. Cisplatin 153-162 heme oxygenase 1 Homo sapiens 94-98 31559456-6 2019 RESULTS: HO-1 expression in HepG2 cells was increased by the treatment of cisplatin (CDDP) and pirarubicin (THP) dose-dependently. Cisplatin 74-83 heme oxygenase 1 Homo sapiens 9-13 31559456-6 2019 RESULTS: HO-1 expression in HepG2 cells was increased by the treatment of cisplatin (CDDP) and pirarubicin (THP) dose-dependently. Cisplatin 85-89 heme oxygenase 1 Homo sapiens 9-13 31559456-7 2019 In HO-1 knockdown HepG2 cells, the HO-1 was not expressed and the percentage of trypan blue-positive cells (dead cells) was significantly increased after treatment of CDDP and THP. Cisplatin 167-171 heme oxygenase 1 Homo sapiens 3-7 31559456-11 2019 CONCLUSION: The cytotoxic effects of CDDP and THP were both enhanced under HO-1 knockdown conditions as well as under conditions that inhibit the activation pathway of HO-1 by EGFR inhibitors. Cisplatin 37-41 heme oxygenase 1 Homo sapiens 75-79 31559456-11 2019 CONCLUSION: The cytotoxic effects of CDDP and THP were both enhanced under HO-1 knockdown conditions as well as under conditions that inhibit the activation pathway of HO-1 by EGFR inhibitors. Cisplatin 37-41 heme oxygenase 1 Homo sapiens 168-172 31423266-0 2019 Stimulated upregulation of HO-1 is associated with inadequate response of gastric and ovarian cancer cell lines to hyperthermia and cisplatin treatment. Cisplatin 132-141 heme oxygenase 1 Homo sapiens 27-31 31456942-0 2019 SIRT5 Promotes Cisplatin Resistance in Ovarian Cancer by Suppressing DNA Damage in a ROS-Dependent Manner via Regulation of the Nrf2/HO-1 Pathway. Cisplatin 15-24 heme oxygenase 1 Homo sapiens 133-137 31456942-6 2019 Mechanistically, we show that SIRT5 contributes to cisplatin resistance in ovarian cancer by suppressing cisplatin-induced DNA damage in a reactive oxygen species (ROS)-dependent manner via regulation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway. Cisplatin 51-60 heme oxygenase 1 Homo sapiens 259-275 31456942-6 2019 Mechanistically, we show that SIRT5 contributes to cisplatin resistance in ovarian cancer by suppressing cisplatin-induced DNA damage in a reactive oxygen species (ROS)-dependent manner via regulation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway. Cisplatin 51-60 heme oxygenase 1 Homo sapiens 277-281 31456942-6 2019 Mechanistically, we show that SIRT5 contributes to cisplatin resistance in ovarian cancer by suppressing cisplatin-induced DNA damage in a reactive oxygen species (ROS)-dependent manner via regulation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway. Cisplatin 105-114 heme oxygenase 1 Homo sapiens 259-275 31456942-6 2019 Mechanistically, we show that SIRT5 contributes to cisplatin resistance in ovarian cancer by suppressing cisplatin-induced DNA damage in a reactive oxygen species (ROS)-dependent manner via regulation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway. Cisplatin 105-114 heme oxygenase 1 Homo sapiens 277-281 31815138-0 2019 Sirt5 Attenuates Cisplatin-Induced Acute Kidney Injury through Regulation of Nrf2/HO-1 and Bcl-2. Cisplatin 17-26 heme oxygenase 1 Homo sapiens 82-86 31815138-12 2019 The levels of Nrf2, HO-1, and Bcl-2 proteins in HK-2 cells were also decreased after CDDP treatment. Cisplatin 85-89 heme oxygenase 1 Homo sapiens 20-24 31815138-15 2019 Together, the results demonstrated that Sirt5 attenuated cisplatin-induced apoptosis and mitochondrial injury in human kidney HK-2 cells, possibly through the regulation of Nrf2/HO-1 and Bcl-2. Cisplatin 57-66 heme oxygenase 1 Homo sapiens 178-182 31423266-4 2019 In OVCAR-3 cells, cisplatin increased HO-1 mRNA expression by 3.73-fold under normothermia and 2.4-fold under hyperthermia; furthermore, these factors similarly increased HO-1 protein expression levels. Cisplatin 18-27 heme oxygenase 1 Homo sapiens 38-42 31423266-4 2019 In OVCAR-3 cells, cisplatin increased HO-1 mRNA expression by 3.73-fold under normothermia and 2.4-fold under hyperthermia; furthermore, these factors similarly increased HO-1 protein expression levels. Cisplatin 18-27 heme oxygenase 1 Homo sapiens 171-175 31423266-6 2019 HO-1-silencing under normothermia increased apoptotic rates in cisplatin-treated OVCAR-3 cells by 2.07-fold, and hyperthermia enhanced the effect by 3.09-fold. Cisplatin 63-72 heme oxygenase 1 Homo sapiens 0-4 31423266-13 2019 In tumors with highly inducible HO-1, prior silencing of this gene could improve the cellular response to hyperthermia and cisplatin. Cisplatin 123-132 heme oxygenase 1 Homo sapiens 32-36 29707997-12 2018 HO-1 is a promising target for prevention and/or treatment of cisplatin-induced nephrotoxicity. Cisplatin 62-71 heme oxygenase 1 Homo sapiens 0-4 31056260-10 2019 Importantly, CDDP combined with LY294002, inhibitor of phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) signaling, markedly decreased the expression of NRF2, HO-1, NQO1 and GCLC in drug-resistant cervical cancer cells. Cisplatin 13-17 heme oxygenase 1 Homo sapiens 176-180 29039478-0 2017 Phosphorylation of eIF2alpha suppresses cisplatin-induced p53 activation and apoptosis by attenuating oxidative stress via ATF4-mediated HO-1 expression in human renal proximal tubular cells. Cisplatin 40-49 heme oxygenase 1 Homo sapiens 137-141 29039478-11 2017 Furthermore, cisplatin induced the expression of activating transcription factor 4 (ATF4) and heme oxygenase-1 (HO-1) that were enhanced by Sal003 and reduced by PERK knockdown. Cisplatin 13-22 heme oxygenase 1 Homo sapiens 94-110 27375080-0 2016 Propyl gallate sensitizes human lung cancer cells to cisplatin-induced apoptosis by targeting heme oxygenase-1 for TRC8-mediated degradation. Cisplatin 53-62 heme oxygenase 1 Homo sapiens 94-110 29039478-11 2017 Furthermore, cisplatin induced the expression of activating transcription factor 4 (ATF4) and heme oxygenase-1 (HO-1) that were enhanced by Sal003 and reduced by PERK knockdown. Cisplatin 13-22 heme oxygenase 1 Homo sapiens 112-116 29039478-12 2017 Taken together, these results suggest that phosphorylation of eIF2alpha suppresses cisplatin-induced p53 activation and apoptosis by attenuating oxidative stress via ATF4-mediated HO-1 expression in HK-2 cells, as ATF4 expression is usually dependent on the phosphorylation of eIF2alpha and may also transcriptionally induce the expression of HO-1 in response to oxidative stress. Cisplatin 83-92 heme oxygenase 1 Homo sapiens 180-184 29039478-12 2017 Taken together, these results suggest that phosphorylation of eIF2alpha suppresses cisplatin-induced p53 activation and apoptosis by attenuating oxidative stress via ATF4-mediated HO-1 expression in HK-2 cells, as ATF4 expression is usually dependent on the phosphorylation of eIF2alpha and may also transcriptionally induce the expression of HO-1 in response to oxidative stress. Cisplatin 83-92 heme oxygenase 1 Homo sapiens 343-347 27375080-5 2016 PG also significantly enhanced the sensitivity of NSCLC cells to cisplatin-induced apoptosis, and this effect was attenuated by overexpression of HO-1. Cisplatin 65-74 heme oxygenase 1 Homo sapiens 146-150 25272046-0 2014 Long-term aerobic exercise protects against cisplatin-induced nephrotoxicity by modulating the expression of IL-6 and HO-1. Cisplatin 44-53 heme oxygenase 1 Homo sapiens 118-122 26801320-0 2016 Inhibition of heme oxygenase-1 enhances the chemosensitivity of laryngeal squamous cell cancer Hep-2 cells to cisplatin. Cisplatin 110-119 heme oxygenase 1 Homo sapiens 14-30 26801320-2 2016 In this research we proved that cisplatin induced cell injuries and heme oxygenase-1 (HO-1) expression in laryngeal squamous cell cancer Hep-2 cells through ROS generation. Cisplatin 32-41 heme oxygenase 1 Homo sapiens 68-84 26801320-2 2016 In this research we proved that cisplatin induced cell injuries and heme oxygenase-1 (HO-1) expression in laryngeal squamous cell cancer Hep-2 cells through ROS generation. Cisplatin 32-41 heme oxygenase 1 Homo sapiens 86-90 26801320-3 2016 The induction of HO-1 clearly protected Hep-2 cells from cisplatin-induced cell death and ROS reaction, and the inhibitor of HO-1 enhanced the cell death and ROS generation induced by cisplatin. Cisplatin 57-66 heme oxygenase 1 Homo sapiens 17-21 26801320-3 2016 The induction of HO-1 clearly protected Hep-2 cells from cisplatin-induced cell death and ROS reaction, and the inhibitor of HO-1 enhanced the cell death and ROS generation induced by cisplatin. Cisplatin 184-193 heme oxygenase 1 Homo sapiens 125-129 26801320-4 2016 Furthermore, the HO-1 expression induced by cisplatin was strongly inhibited by the knockdown of nuclear factor-erythroid-2-related factor-2 (Nrf-2), and the oxidative damages induced by cisplatin were significantly enhanced. Cisplatin 44-53 heme oxygenase 1 Homo sapiens 17-21 26801320-4 2016 Furthermore, the HO-1 expression induced by cisplatin was strongly inhibited by the knockdown of nuclear factor-erythroid-2-related factor-2 (Nrf-2), and the oxidative damages induced by cisplatin were significantly enhanced. Cisplatin 187-196 heme oxygenase 1 Homo sapiens 17-21 26801320-5 2016 Therefore, it may be concluded that the inhibition of HO-1 or the knockdown of Nrf-2 significantly enhanced cisplatin"s anticancer effects on Hep-2 cells. Cisplatin 108-117 heme oxygenase 1 Homo sapiens 54-58 26801320-6 2016 In clinic, with the overexpression of HO-1 in laryngeal squamous cancer tissues, the combination of cisplatin with the inhibitor of HO-1 or Nrf-2 siRNA may act as a new method to the treatment of laryngeal squamous cancer. Cisplatin 100-109 heme oxygenase 1 Homo sapiens 38-42 26801320-6 2016 In clinic, with the overexpression of HO-1 in laryngeal squamous cancer tissues, the combination of cisplatin with the inhibitor of HO-1 or Nrf-2 siRNA may act as a new method to the treatment of laryngeal squamous cancer. Cisplatin 100-109 heme oxygenase 1 Homo sapiens 132-136 25988128-8 2014 EGCG improved efficacy of cisplatin treatment in HeLa cells by regulating NFkappaB p65, COX-2, p-Akt, and p-mTOR pathways, whereas it increased the expression levels of Nrf2/HO-1 in combined therapy. Cisplatin 26-35 heme oxygenase 1 Homo sapiens 174-178 26573721-0 2016 Vanadium(III)-L-cysteine protects cisplatin-induced nephropathy through activation of Nrf2/HO-1 pathway. Cisplatin 34-43 heme oxygenase 1 Homo sapiens 91-95 25843086-3 2015 In this study, we found that the expression levels of Nrf2 and its target genes GCLC, HO-1, NQO1 were significantly higher in cisplatin-resistant A549 (A549/CDDP) cells than those in A549 cells, and this resistance was partially reversed by Nrf2 siRNA. Cisplatin 126-135 heme oxygenase 1 Homo sapiens 86-90 18992762-5 2009 CDDP significantly increased renal abundances of HO-1, HSP60, HSP72 and HSP90 at days 1, 3, and 5. Cisplatin 0-4 heme oxygenase 1 Homo sapiens 49-53 24642709-0 2014 Capsaicin ameliorates cisplatin-induced renal injury through induction of heme oxygenase-1. Cisplatin 22-31 heme oxygenase 1 Homo sapiens 74-90 24642709-11 2014 These results suggest that capsaicin has protective effects against cisplatin-induced renal dysfunction through induction of HO-1 as well as inhibition oxidative stress and inflammation. Cisplatin 68-77 heme oxygenase 1 Homo sapiens 125-129 24300974-0 2014 Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-kappaB and MAPK/HO-1 signalling. Cisplatin 42-51 heme oxygenase 1 Homo sapiens 139-143 24300974-8 2014 Importantly, it was found that, followed by CDDP treatment, GA could inhibit NF-kappaB and mitogen-activated protein kinase (MAPK)/heme oxygenase-1 (HO-1) signalling pathways, which have been validated to reduce ROS release and confer CDDP resistance. Cisplatin 44-48 heme oxygenase 1 Homo sapiens 131-147 24300974-8 2014 Importantly, it was found that, followed by CDDP treatment, GA could inhibit NF-kappaB and mitogen-activated protein kinase (MAPK)/heme oxygenase-1 (HO-1) signalling pathways, which have been validated to reduce ROS release and confer CDDP resistance. Cisplatin 44-48 heme oxygenase 1 Homo sapiens 149-153 24300974-8 2014 Importantly, it was found that, followed by CDDP treatment, GA could inhibit NF-kappaB and mitogen-activated protein kinase (MAPK)/heme oxygenase-1 (HO-1) signalling pathways, which have been validated to reduce ROS release and confer CDDP resistance. Cisplatin 235-239 heme oxygenase 1 Homo sapiens 149-153 24300974-10 2014 Moreover, our results indicated that the combination of CDDP and GA exerted increased antitumour effects on A549 xenograft models through inhibiting NF-kappaB, HO-1, and subsequently inducing apoptosis. Cisplatin 56-60 heme oxygenase 1 Homo sapiens 160-164 22421218-0 2012 Smad7 sensitizes A549 lung cancer cells to cisplatin-induced apoptosis through heme oxygenase-1 inhibition. Cisplatin 43-52 heme oxygenase 1 Homo sapiens 79-95 22421218-4 2012 The HO-1 protein level was elevated in cisplatin-resistant A549 human lung cancer cells and blockade of HO-1 activation sensitized the cells to apoptosis. Cisplatin 39-48 heme oxygenase 1 Homo sapiens 4-8 22421218-4 2012 The HO-1 protein level was elevated in cisplatin-resistant A549 human lung cancer cells and blockade of HO-1 activation sensitized the cells to apoptosis. Cisplatin 39-48 heme oxygenase 1 Homo sapiens 104-108 22421218-7 2012 Consistently, Smad7 sensitized A549 cells to cisplatin-induced apoptosis and these effects were dependent on HO-1 and Akt inhibition. Cisplatin 45-54 heme oxygenase 1 Homo sapiens 109-113 19375813-2 2010 We investigated involvement of HO-1 in chemoresistance of cisplatin in human lung epithelial adenocarcinoma cell line, A549, which constitutively expressed HO-1. Cisplatin 58-67 heme oxygenase 1 Homo sapiens 31-35 22326969-6 2012 Instead, the over expression of anti-apoptotic Bcl-2, anti-oxidative heme oxygenase-1 (HO-1) and cell cycle regulator p16INK4 seemed to be more important for the gaining of cisplatin in these human urothelial carcinoma cell. Cisplatin 173-182 heme oxygenase 1 Homo sapiens 69-85 22490514-8 2012 Whether the induction or inhibition of HO-1 by cobalt-protoporphyrin-IX (CoPP) or zinc-protoporphyrin-IX (ZnPP) could affect the sensitivity of MKN-45 cells to cisplatin was also studied. Cisplatin 160-169 heme oxygenase 1 Homo sapiens 39-43 22490514-10 2012 HO-1 overexpression could lead to an increased resistance to cisplatin, whereas down-regulation of HO-1 expression by siRNA or chemical inhibition of HO-1 could lead to increased chemosensitivity to cisplatin in MKN-45 cells. Cisplatin 61-70 heme oxygenase 1 Homo sapiens 0-4 22490514-10 2012 HO-1 overexpression could lead to an increased resistance to cisplatin, whereas down-regulation of HO-1 expression by siRNA or chemical inhibition of HO-1 could lead to increased chemosensitivity to cisplatin in MKN-45 cells. Cisplatin 199-208 heme oxygenase 1 Homo sapiens 99-103 22490514-10 2012 HO-1 overexpression could lead to an increased resistance to cisplatin, whereas down-regulation of HO-1 expression by siRNA or chemical inhibition of HO-1 could lead to increased chemosensitivity to cisplatin in MKN-45 cells. Cisplatin 199-208 heme oxygenase 1 Homo sapiens 99-103 21552291-8 2011 Although p53 and its classical targets such as p21 and Mdm2 are activated by both H(2)O(2) and CDDP, we found that the expression of haeme-oxygenase-1 (HO-1)-an antioxidant and antiapoptotic protein-was directly induced only upon H(2)O(2) treatment in a p53-dependent manner. Cisplatin 95-99 heme oxygenase 1 Homo sapiens 152-156 21857081-10 2011 These results demonstrate that the expression of HO-1 induced by phloretin is mediated by both the JNK pathway and Nrf2; the expression inhibits cisplatin-induced apoptosis in HEI-OC1 cells. Cisplatin 145-154 heme oxygenase 1 Homo sapiens 49-53 19937094-0 2010 Kaempferol suppresses cisplatin-induced apoptosis via inductions of heme oxygenase-1 and glutamate-cysteine ligase catalytic subunit in HEI-OC1 cell. Cisplatin 22-31 heme oxygenase 1 Homo sapiens 68-84 19937094-10 2010 CONCLUSION: The expression of HO-1 by kaempferol inhibits cisplatin-induced apoptosis in HEI-OC1 cells, and the mechanism of protective effect is also associated with its inductive effect of GCLC expression. Cisplatin 58-67 heme oxygenase 1 Homo sapiens 30-34 19375813-3 2010 We found that treatment with cisplatin further augmented HO-1 expression, which was associated with activation of the epidermal growth factor receptor (EGFR) mediated signaling pathway and subsequent nuclear translocation of NF-kappaB. Cisplatin 29-38 heme oxygenase 1 Homo sapiens 57-61 19375813-4 2010 In concordance with the findings, treatment with EGFR-selective tyrosine kinase inhibitor (AG1478) or an Akt inhibitor, which interfere with the post-EGFR signaling pathway, suppressed cisplatin induced HO-1 expression. Cisplatin 185-194 heme oxygenase 1 Homo sapiens 203-207 19375813-7 2010 Collectively, the results indicate that resistance to cisplatin in A549 cells is associated with HO-1 through EGFR mediated signaling pathway including activation of the PI3k/Akt and NF-kappaB systems. Cisplatin 54-63 heme oxygenase 1 Homo sapiens 97-101 19484149-10 2009 In contrast to annexin A11, HMOX1 immunoreactivity positively correlated with in vitro cisplatin resistance in ovarian cancers. Cisplatin 87-96 heme oxygenase 1 Homo sapiens 28-33 18584244-0 2008 Evidence that cisplatin-induced auditory damage is attenuated by downregulation of pro-inflammatory cytokines via Nrf2/HO-1. Cisplatin 14-23 heme oxygenase 1 Homo sapiens 119-123 18584244-2 2008 We report here that flunarizine markedly attenuates cisplatin-induced pro-inflammatory cytokine secretion and their messenger RNA transcription as well as cisplatin cytotoxicity through the activation of Nrf2/HO-1 and downregulation of NF-kappaB. Cisplatin 52-61 heme oxygenase 1 Homo sapiens 209-213 18584244-8 2008 These results indicate that flunarizine induces a protective effect against cisplatin ototoxicity through the downregulation of NF-kappaB by Nrf2/HO-1 activation and the resulting inhibition of pro-inflammatory cytokine production in vitro and in vivo. Cisplatin 76-85 heme oxygenase 1 Homo sapiens 146-150 18584244-3 2008 In HEI-OC1 cells, overexpression of Nrf2/HO-1 by gene transfer or pharmacological approaches attenuated cisplatin-induced cytotoxicity and pro-inflammatory cytokine production. Cisplatin 104-113 heme oxygenase 1 Homo sapiens 41-45 16485034-5 2006 Furthermore, both pharmacological inhibition and siRNA transfection of HO-1 completely abolished the flunarizine-mediated protection of HEI-OC1 cells and the primary rat (P2) organ of Corti explants from cisplatin. Cisplatin 204-213 heme oxygenase 1 Homo sapiens 71-75 16485034-0 2006 Flunarizine induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection of auditory cells from cisplatin. Cisplatin 118-127 heme oxygenase 1 Homo sapiens 64-80 18598163-0 2008 Luteolin suppresses cisplatin-induced apoptosis in auditory cells: possible mediation through induction of heme oxygenase-1 expression. Cisplatin 20-29 heme oxygenase 1 Homo sapiens 107-123 18598163-8 2008 These results demonstrate that the expression of HO-1 by luteolin is mediated by the ERK pathway, and also that the activating of HO-1 inhibits cisplatin-induced apoptosis in HEI-OC1 1 cells. Cisplatin 144-153 heme oxygenase 1 Homo sapiens 49-53 18598163-8 2008 These results demonstrate that the expression of HO-1 by luteolin is mediated by the ERK pathway, and also that the activating of HO-1 inhibits cisplatin-induced apoptosis in HEI-OC1 1 cells. Cisplatin 144-153 heme oxygenase 1 Homo sapiens 130-134 18006113-0 2008 Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Cisplatin 107-116 heme oxygenase 1 Homo sapiens 27-43 18006113-5 2008 A549 cells are less susceptible to cisplatin cytotoxicity than other lung cancer cell lines, concomitant with increases in HO-1 expression and MAPK phosphorylation in a time-dependent fashion. Cisplatin 35-44 heme oxygenase 1 Homo sapiens 123-127 18006113-6 2008 Furthermore, inhibition of HO-1 by siRNA and a specific HO-1 inhibitor ZnPP augments cisplatin cytotoxicity toward A549 cells. Cisplatin 85-94 heme oxygenase 1 Homo sapiens 27-31 18006113-6 2008 Furthermore, inhibition of HO-1 by siRNA and a specific HO-1 inhibitor ZnPP augments cisplatin cytotoxicity toward A549 cells. Cisplatin 85-94 heme oxygenase 1 Homo sapiens 56-60 18006113-7 2008 Pharmacologic suppression of HO-1 activity resulted in a marked increase in the ROS generation in cisplatin-treated cells. Cisplatin 98-107 heme oxygenase 1 Homo sapiens 29-33 18006113-8 2008 In addition, pharmacologic inhibitors of MAPK suppressed the induction of HO-1 and Nrf2 expression by cisplatin. Cisplatin 102-111 heme oxygenase 1 Homo sapiens 74-78 18006113-9 2008 These findings suggest that HO-1 may modulate the chemosensitivity of lung cancer A549 cells to cisplatin through the MAPK-Nrf2 pathway. Cisplatin 96-105 heme oxygenase 1 Homo sapiens 28-32 17418561-0 2007 Piperine protects cisplatin-induced apoptosis via heme oxygenase-1 induction in auditory cells. Cisplatin 18-27 heme oxygenase 1 Homo sapiens 50-66 17418561-8 2007 These results demonstrate that the expression of HO-1 by piperine is mediated by both JNK pathway and Nrf2, and the expression inhibits cisplatin-induced apoptosis in HEI-OC1 cells. Cisplatin 136-145 heme oxygenase 1 Homo sapiens 49-53 16485034-6 2006 These results suggest that Nrf2-driven transcriptional activation of ARE through PI3K-Akt signaling augments the generation of HO-1, which may be a critically important determinant in cellular response toward cisplatin and the cytoprotective effect of flunarizine against cisplatin. Cisplatin 209-218 heme oxygenase 1 Homo sapiens 127-131 16485034-6 2006 These results suggest that Nrf2-driven transcriptional activation of ARE through PI3K-Akt signaling augments the generation of HO-1, which may be a critically important determinant in cellular response toward cisplatin and the cytoprotective effect of flunarizine against cisplatin. Cisplatin 272-281 heme oxygenase 1 Homo sapiens 127-131 12420741-0 2002 Management of oxidative stress by heme oxygenase-1 in cisplatin-induced toxicity in renal tubular cells. Cisplatin 54-63 heme oxygenase 1 Homo sapiens 34-50 16678019-0 2006 Heme oxygenase-1 attenuates the cisplatin-induced apoptosis of auditory cells via down-regulation of reactive oxygen species generation. Cisplatin 32-41 heme oxygenase 1 Homo sapiens 0-16 16678019-3 2006 Herein, we demonstrate that pharmacologic induction of HO-1 along with catalytic activation significantly suppressed apoptosis of HEI-OC1 cells induced by cisplatin. Cisplatin 155-164 heme oxygenase 1 Homo sapiens 55-59 16678019-4 2006 Studies of ectopic expression of pcDNA3-HO-1 and siRNA of HO-1 further revealed the protective role of HO-1 against cisplatin in HEI-OC1 cells. Cisplatin 116-125 heme oxygenase 1 Homo sapiens 58-62 16678019-4 2006 Studies of ectopic expression of pcDNA3-HO-1 and siRNA of HO-1 further revealed the protective role of HO-1 against cisplatin in HEI-OC1 cells. Cisplatin 116-125 heme oxygenase 1 Homo sapiens 58-62 16678019-5 2006 Among the catabolic metabolites of HO-1, both carbon monoxide (CO) and bilirubin were directly involved in the protective role of HO-1 against cisplatin through inhibition of reactive oxygen species generation. Cisplatin 143-152 heme oxygenase 1 Homo sapiens 35-39 16678019-5 2006 Among the catabolic metabolites of HO-1, both carbon monoxide (CO) and bilirubin were directly involved in the protective role of HO-1 against cisplatin through inhibition of reactive oxygen species generation. Cisplatin 143-152 heme oxygenase 1 Homo sapiens 130-134 12420741-1 2002 Induction of heme oxygenase-1 (HO-1) may serve as an immediate protective response during treatment with the cytostatic drug cisplatin (CDDP). Cisplatin 125-134 heme oxygenase 1 Homo sapiens 13-29 12420741-1 2002 Induction of heme oxygenase-1 (HO-1) may serve as an immediate protective response during treatment with the cytostatic drug cisplatin (CDDP). Cisplatin 136-140 heme oxygenase 1 Homo sapiens 13-29 10807584-6 2000 In vitro studies in human renal proximal tubule cells demonstrate that hemin, an inducer of HO-1, significantly attenuated cisplatin-induced apoptosis and necrosis, whereas inhibition of HO-1 enzyme activity reversed the cytoprotective effect. Cisplatin 123-132 heme oxygenase 1 Homo sapiens 92-96